Executive Vice President, Chief Commercial Officer · Heron Therapeutics, Inc. (HRTX)

David Szekeres

A named executive officer of Heron Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$1,429,231

Salary $533,013Stock awards $441,456

FY2021: $1,829,431

2nd of 3 named executive officers at Heron Therapeutics by FY2022 total.

3 named officers on file for Heron Therapeutics, FY2022

David Szekeres’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • HRTX’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Heron Therapeutics’s whole pay program stands against its peers

  • Heron Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on HRTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 1, 2023 (DEF 14A).

Free

Get David Szekeres’s full pay file as a PDF — free

More than this page: up to 10 years of David’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

David Szekeres compensation by year

Heron Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Heron Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022
Salary$476,910$494,400$533,013
Bonus$0$0$0
Stock awards$314,400$583,626$441,456
Option awards$1,500,673$535,147$235,482
Non-equity incentive$161,664$197,760$199,880
Pension and deferred compensation$0$0$0
All other$8,550$18,498$19,400
Total$2,462,197$1,829,431$1,429,231

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Heron Therapeutics, Inc. DEF 14A filed May 1, 2023, accession 0000950170-23-016042, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Heron Therapeutics, Inc. filed document, accession 0000950170-23-016042. Every figure is read from that document and cited to the page and table it appears in. Filed May 1, 2023.

$2.5M
$1.8M
$1.4M
FY20
FY21
FY22
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
PSU116,163$290,408—
RSU49,788$124,470—
RSU37,064$92,660—
PSU10,000$25,000—
Option71,500—$15.72
Option56,703—$10.55
Option145,216—$3.17
Option28,750—$25.02

Per the Outstanding Equity Awards at Fiscal Year-End table in Heron Therapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Heron Therapeutics’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Kimberly ManhardExecutive Vice President, Drug Development$1,447,107
David Szekeres · this pageExecutive Vice President, Chief Commercial Officer$1,429,231
Barry QuartFormer Chief Executive Officer$1,145,704

The full Heron Therapeutics compensation record

free company brief

This page is one person within Heron Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Heron Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

David Szekeres's compensation dossier · One-time report. No refunds.